Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of IPH1101 + IL-2 with or without dacarbazine in metastatic melanoma
2007-007265-20Phase 2Active
- Sponsor
- Innate Pharma
- Start
- Jan 2008
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing IPH1101 + IL-2 with IPH1101 + IL-2 + dacarbazine (2 arms). Primary endpoint: Objective response rate (modified RECIST). Started Jan 2008; status: active.
02
Drugs
IPH1101aldesleukindacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-007265-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007265-20.